Humanized Anti-Tac in the treatment of uveitis

本研究的目的是评价人源化抗IL-2受体单克隆抗体（Daclizumab）治疗严重、危及视力、中间和后部非感染性葡萄膜炎患者的安全性和潜在治疗活性，这是一项非随机、开放标签、初探性研究。患有慢性、非感染性双侧、威胁视力的葡萄膜炎并接受至少20 mg泼尼松、环孢霉素、抗代谢药或这些药物的任何组合治疗的患者合格。患者根据标准化的时间表停用这些免疫抑制剂，而最终每4周接受一次Daclizumab输注。抗白细胞介素2受体抗体治疗，以最多4周的间隔静脉内给予，代替标准免疫抑制治疗，似乎在治疗至少7个月的10名患者中的9名中预防了严重威胁视力的眼内炎性疾病的表达，基于主要终点，即每只眼睛从基线视力丧失10个字母或更多。所有患者均能够耐受研究药物，无需降低剂量。- 葡萄膜炎，白细胞介素-2，抗Tac抗体，免疫抑制，-人类受试者

The goal of this study is to evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor monoclonal antibody (Daclizumab) therapy in the treatment of patients with severe, sight-threatening, intermediate and posterior non-infectious uveitis.This is a non-randomized, open-label, pilot study. Patients with chronic, non-infectious bilateral, sight-threatening uveitis who were treated with a minimum of 20 mg of prednisone, cyclosporine, anti- metabolites, or any combination of these agents were eligible. Patients were weaned off these immunosuppressive agents according to a standardized schedule, while ultimately receiving Daclizumab infusions every 4 weeks.Anti-Interleukin 2 receptor antibody therapy, given intravenously with intervals of up to four weeks in lieu of standard immunosuppressive therapy, appeared to prevent the expression of severe sight-threatening intraocular inflammatory disease in nine of ten patients treated for a minimum of seven months, based on the primary end point of a loss of vision of 10 letters or more from baseline in either eye. All patients were able to tolerate the study medications without the need for dose reduction. - uveitis, Interleukin-2, anti-Tac antibody, immunosuppression, - Human Subjects